Impact of Psychotic Symptoms and Concurrent Neuropsychiatric Symptoms on the Quality of Life of People With Dementia Living in Nursing Homes

Aaron Choi MSca, Anthony Martyr PhDa, Linda Clare ScDa,b, Jane Fossey PhDa, Zunera Khan PhDc, Joanne McDermid MSca, Clive Ballard MDa,*

a College of Medicine and Health, University of Exeter, Exeter, United Kingdom
b NIHR Applied Research Collaboration South-West Peninsula, Plymouth, Devon, United Kingdom
c King’s College London, London, United Kingdom

Keywords: Delusions hallucinations agitation anxiety depression

Abstract

Objectives: The aim of the present study was to determine whether psychotic symptoms in people with dementia (PwD) living in nursing homes were associated with reduced quality of life and to understand the additional impact of other concurrent neuropsychiatric symptoms on QoL.

Design: Cross-sectional cohort study (using data from WHELD cohort).

Settings and participants: 971 PwD living in nursing homes participating in the WHELD study.

Methods: The Neuropsychiatric Inventory—Nursing Home (NPI-NH) version was completed by informant interview. We compared mean differences in proxy-rated QoL scores (DEMQOL-Proxy) for PwD experiencing or not experiencing delusions and for PwD experiencing or not experiencing hallucinations. Backward multiple regression was used to determine the added contributions of agitation (Cohen-Mansfield Agitation Inventory), anxiety (NPI-NH-Anxiety), depression (Cornell Scale for Depression in Dementia), dementia severity (Clinical Dementia Rating-sum of boxes score), pain (Abbey Pain Scale), and antipsychotic prescription. Mediation analysis was conducted for agitation, anxiety, and depression.

Results: Presence of both delusions ($P < .001, B = 8.39$) and hallucinations ($P < .001, B = 7.78$) was associated with poorer QoL. Both associations remained significant after controlling for other factors. Agitation, anxiety, and depression partially mediated the relationship between each psychotic symptom and QoL.

Conclusions and Implications: Delusions and hallucinations in PwD are associated with poorer QoL among PwD living in nursing homes. The effects remain significant after adjusting for confounding variables. Direct effects of each symptom maintained significance despite significant mediation by concurrent neuropsychiatric symptoms.

© 2022 The Authors. Published by Elsevier Inc. on behalf of AMDA — The Society for Post-Acute and Long-Term Care Medicine. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
symptoms but have been linked to various potentially harmful outcomes for PwD. Understanding the mediating impact of frequently comorbid neuropsychiatric symptoms on quality of life (QoL) in PwD experiencing psychotic symptoms is an important gap in our current knowledge and may provide new avenues for developing nonpharmacologic treatments to improve QoL in PwD-related psychotic symptoms.

Measures of QoL are frequently used to determine subjective life experience and ability to live well when experiencing dementia and the various symptoms resulting from dementia. In the context of psychotic symptoms, previous studies have indicated that the presence of psychotic symptoms is associated with lower QoL in PwD living in the community and PwD living in nursing homes. Several studies have investigated delusion and hallucinations in PwD and did not find an association with QoL; these studies however had relatively small sample sizes. Other studies that focus on the association between psychotic symptoms and QoL investigated the symptoms as a singular phenomenon rather than delusions and hallucinations separately. Only 2 studies with a large sample cohort have examined the independent impact of delusions and hallucinations on QoL in PwD living in nursing homes, and each study concluded that both delusions and hallucinations were significantly associated with reduced QoL.

Although there appears to be a clear association between reduced QoL and the occurrence of psychotic symptoms in PwD living in nursing homes, what is less clear is whether this is a direct effect or whether other key factors associated with psychotic symptoms and impaired QoL, such as concurrent neuropsychiatric symptoms, dementia severity, chronic pain, and antipsychotic medications, may have an additive role. Crucially, neuropsychiatric symptoms commonly comorbid with psychotic symptoms such as agitation, anxiety, and depression have shown to be heavily associated with reduced QoL. It is therefore important to understand whether these neuropsychiatric symptoms fully mediate the impact of psychotic symptoms on QoL. If psychotic symptoms do not show to have independent association in the presence of other neuropsychiatric symptoms, focus on developing treatment methods for psychotic symptoms in dementia should be secondary to these other neuropsychiatric symptoms.

The aim of the present study is to determine the independent effects of delusions and hallucinations on QoL for PwD living in nursing homes and to elucidate the role of concurrent factors such as concurrent neuropsychiatric symptoms, dementia severity, pain, and antipsychotic prescription in mediating or adding to detrimental impacts on QoL.

Methods

Study Population

In this study, we analyzed baseline data collected as part of the Improving Well-being and Health for People with Dementia (WHELD) study, a 9-month cluster randomized controlled trial conducted in 69 nursing homes in England, recruited from 3 recruitment hubs: South London, North London, and Buckinghamshire. Residents of identified nursing homes were eligible for inclusion if they met criteria for dementia, defined as a score of 1 or greater on the Clinical Dementia Rating (CDR). At baseline, the WHELD cohort comprised 971 PwD. Written consent was provided by PwD when they had mental capacity to provide consent for themselves. Data on PwD were collected through assessments conducted by trained researchers. All measures, except where stated, were completed by members of staff from contributing care homes, subsequently referred to as “informants,” who provided details about the PwD in their care. The WHELD study was reviewed and approved by the Oxford C National Research Ethics Committee (Ref: 13/SC/0281). This study is registered with the ISRCTN Registry (Ref: ISRCTN62237498). Further details are available in the published protocol and trial findings.

Measures

Psychotic symptoms

Delusions and hallucinations were measured using the Neuropsychiatric Inventory—Nursing Home version (NPI-NH). In the NPI-NH informants were asked whether the person with dementia they were caring for was experiencing symptoms in 12 discrete behavioral domains: delusions, hallucinations, agitation and aggression, depression and dysphoria, anxiety, euphoria and elation, apathy and indifference, disinhibition, irritability and lability, aberrant motor behavior, nighttime behavioral disturbances, and appetite and eating changes. For each NPI-NH domain endorsed, the informant was asked to complete a corresponding rating for frequency (1–4) and severity (1–3) within the past week, with higher scores indicating more frequency and severity. For the purposes of this study, the delusions and hallucinations domains were considered as binary categorical variables; that is, we noted the absence or presence of each symptom.

Anxiety

The NPI-NH was also used to evaluate anxiety. Unlike psychotic symptoms, the present study used the NPI ordinal score to assess anxiety. This approach was undertaken to acknowledge the fact that presence of some anxiety is normal whereas the presence of any psychotic symptoms would be construed as an abnormal experience.

QoL

The primary method of assessing QoL in PwD was with the DEMQOL-Proxy, a 31-item interviewer-administered questionnaire. Scores ranged between 31 and 124, with higher scores indicating better QoL.

Agitation

The Cohen-Mansfield Agitation Inventory (CMAI) was used to rate agitated behavior. The CMAI comprises 29 items related to agitated behavior, each of which is rated on a 7-point scale of frequency, with a total score range of 29 to 203. Higher scores indicate more severe agitation.

Depression

The Cornell Scale for Depression in Dementia (CSDD) was used to assess signs and symptoms of major depression in PwD, with a score range from 0 to 38, with higher scores indicating more severe depression.

Pain

The Abbey Pain Scale was used as an observational brief indicator of pain for PwD. The scale is rated on 6 nonverbal indicators of pain, with a total score range of to 18. Higher scores indicate more severe pain experienced.

Dementia severity

The CDR is a scale used to quantify the severity of symptoms of dementia. Scores are obtained through semistructured interviews of residents and informants, and cognitive functioning is rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. For the purpose of the present study, we used the CDR sums of boxes score, which was obtained by summing each of the domain box scores.
The range of scores for CDR sums of boxes is 0–18. Higher scores indicate more severe dementia.

**Antipsychotic prescription**

Information on antipsychotic prescription over the previous 12 months was taken from participants’ medication charts at each nursing home. The present analysis uses a binary measure of whether individuals were prescribed antipsychotic drugs at the time of the baseline assessment.

**Data Analysis**

All statistical analyses were carried out using IBM SPSS Statistics v26. For the first research question, unadjusted linear regressions were used to determine whether the presence of delusions and hallucinations respectively was associated with a lower QoL score.

For the second research question, a backwards stepwise multiple regression was used to determine the best overall predictive model of impaired QoL based on delusions, hallucinations, agitation, depression, anxiety, dementia severity, antipsychotic usage, and pain. To correct for multiple comparisons, findings were only reported if they were significant at the 5% level after Holm-Bonferroni correction.

For the third research question, parallel multiple mediator analyses were used to determine the mediating effect of agitation, anxiety, and depression on the relationship between each psychotic symptom and QoL. The analyses were performed using PROCESS macro.

**Results**

Of the 971 participants, 687 (70.1%) were female and the mean age was 84.57 (SD 8.98). The prevalence of delusions and hallucinations was 17.5% and 14.6%, respectively, and 20% of participants were prescribed atypical antipsychotics. People who were experiencing delusions did not significantly differ in age (t(968) = −.25, P = .787) or sex (χ²(1) = 0.447, P = .504). Similarly, people experiencing hallucinations did not differ in age (t(969) = −.87, P = .098) or sex (χ²(1) = 0.497, P = .487). The full characteristics are summarized in Table 1, and a characteristic difference in those who experience psychotic symptoms are summarized in Supplemental Table 1.

**Association of Psychotic Symptoms With Impaired QoL**

The first research question focused on whether there were associations between the presence of informant-rated delusions and hallucinations, respectively, and the DEMQOL-Proxy total score. In the unadjusted model, the presence of both delusions and hallucinations, respectively, were both strongly associated with lower DEMQOL-Proxy scores (delusions B = −8.39, P < .001; hallucinations B = −7.78, P < .001; see Tables 2 and 3).

In the backwards stepwise regression model (including dementia severity, other concurrent neuropsychiatric symptoms, pain, and antipsychotic prescriptions), the main effect for delusions remained statistically significant but the beta coefficient was attenuated by nearly 3 points. The model explained 29% of the variance, with concurrent depression the biggest predictor for reduced QoL. Antipsychotic prescription was dropped from the final model; see Table 2. All variables included in the final model remained significant after Holm-Bonferroni adjustment.

Similarly, the main effect for hallucinations also remained statistically significant in the adjusted model, but the beta coefficient was attenuated by nearly 3 points. The model explained 29% of the variance, with concurrent depression as the biggest predictor of reduced QoL. The backwards stepwise model did not include antipsychotic medication in the final model; see Table 3. All variables included in the final model remained significant after Holm-Bonferroni adjustment.

Therefore, the individual effect of delusions and hallucinations on QoL were similar.

Following on from the regression model, the key question was how the experience of other neuropsychiatric symptoms mediated the relationship between psychotic symptoms and QoL in dementia. Delusions, agitation, anxiety, and depression had a negative and significant direct effect on QoL, but there were also indirect effects (IEs) of delusions on QoL mediated via agitation (IE = −1.56, 95% CI −2.5, −0.72), anxiety (IE = −1.21, 95% CI −1.89, −0.62), and depression (IE = −2.34, 95% CI −3.25, −1.57) (see Figure 1).

Similarly, hallucinations, agitation, anxiety, and depression had a negative and significant direct effect on QoL, but again there were indirect effects of hallucinations on QoL mediated via agitation (IE = −1.70, 95% CI −2.72, −0.84), anxiety (IE = −1.13, 95% CI −1.80, −0.58), and depression (IE = −2.46, 95% CI −3.51, −1.54) (see Figure 2).

**Table 1**

| Characteristics of the People With Dementia (N = 971) |
|-----------------------------------------------|
| Demographic Characteristic | n (%) or Mean (SD); n |
| Sex                             | Male | 284 (29.2) | 971 |
|                               | Female | 687 (70.8) | 971 |
| Ethnicity                      | Asian | 9 (0.9) | |
|                               | African | 11 (1.1) | |
|                               | Black Caribbean | 25 (2.6) | |
|                               | White | 916 (94.4) | |
|                               | Mixed | 6 (0.6) | 971 |
|                               | Other | 4 (0.4) | 971 |
| Marital status                 | Single | 120 (12.4) | |
|                               | Married | 205 (21.1) | |
|                               | Divorced | 58 (6.0) | |
|                               | Separated | 7 (0.7) | |
|                               | Widowed | 563 (58.0) | |
|                               | Long-term partnership | 7 (0.7) | |
|                               | Missing | 11 (1.1) | |
| Delusions                      | No | 800 (82.4) | |
|                               | Yes | 170 (17.5) | |
| Hallucinations                 | No | 829 (85.4) | |
|                               | Yes | 142 (14.6) | |
| Antipsychotic prescription     | No | 194 (20.0) | |
|                               | Yes | 755 (77.8) | |
|                                 | Missing | 22 (2.2) | |
| Age                            | 84.57 (8.98); 971 |
| DEMQOL-Proxy                   | 101.48 (12.93); 964 |
| Clinical Dementia Rating–sum of boxes score | 13.78 (3.55); 971 |
| Cohen-Mansfield Agitation Inventory | 48.32 (19.36); 969 |
| NPI-NH–Anxiety                 | 1.45 (2.80); 970 |
| Cornell Scale for Depression in Dementia | 6.22 (3.07); 960 |
| Abbey Pain Scale               | 2.29 (2.81); 967 |

**Table 2**

| Unadjusted and Adjusted Multiple Linear Regression on the Relationship of Delusions to QoL Scores as Measured by the DEMQOL-Proxy |
|-------------------------------------------------------------------------------------------------|
| B | SE | β | t | P |
|-------------------------------------------------------------------------------------------------|
| Unadjusted Delusion | −8.39 | 1.06 | −0.25 | −7.901 | <.001 |
| Adjusted Delusion | −2.79 | 1.00 | −0.08 | −2.79 | .005 |
| Agitation          | −0.02 | 0.15 | −0.15 | −4.41 | <.001 |
| Anxiety            | −0.68 | 0.09 | −0.29 | −7.94 | <.001 |
| Depression         | −0.74 | 0.15 | −0.15 | −4.60 | <.001 |
| Dementia severity  | 0.46  | 0.10 | 0.13  | 4.57  | <.001 |
| Pain               | −0.30 | 0.14 | −0.07 | −2.18 | .029 |

R² = 0.293 (adjusted R² = 0.289).
Table 3
Unadjusted and Adjusted Multiple Linear Regression on the Relationship of Hallucinations to QoL Scores as Measured by the DEMQOL-Proxy

|                      | B    | SE   | β    | t    | P    |
|----------------------|------|------|------|------|------|
| Unadjusted           |      |      |      |      |      |
| Hallucination        | −7.78| 1.15 | −0.21| −6.77| <.001|
| Hallucination        | −2.83| 1.07 | −0.08| −2.65| .008 |
| Agitation            | −0.10| 0.02 | −0.15| −4.47| <.001|
| Anxiety              | −0.69| 0.15 | −0.15| −4.71| <.001|
| Depression           | −0.74| 0.09 | −0.29| −8.03| <.001|
| Dementia severity    | 0.51 | 0.10 | 0.14 | 4.00 | <.001|
| Pain                 | −0.28| 0.14 | −0.06| −2.01| .044 |

R² = 0.290 (adjusted R² = 0.286).

Discussion

The present study investigated the impact of delusions and hallucinations on proxy-rated QoL in a large cohort of PwD living in nursing homes. Both delusions and hallucinations were significantly associated with lower QoL, in the unadjusted and adjusted regression models. Key concurrent neuropsychiatric symptoms such as increased agitation, anxiety, and depression were associated with delusions and hallucinations and were important mediating factors in the relationship between psychotic symptoms and impaired QoL in PwD. This is relatively lower to previous studies investigating predictors of QoL in PwD.11,21,25 This is likely due to focusing on selected neuropsychiatric symptoms that have been known to be strongly associated to reduced QoL rather than including all neuropsychiatric symptoms.

The strengths of the present study include the use of an analysis model incorporating dementia severity, concurrent neuropsychiatric symptoms, antipsychotic prescription, and pain, the large sample size, and the use of mediation analyses.

The study was limited by the use of a proxy-rated instrument for measuring QoL rather than a self-rated tool, as this does not give a direct insight into the perspective of PwD on their QoL; however, modest levels of agreement have been found between ratings by caregivers and PwD using DEMQOL-Proxy and DEMQOL44 and the use of proxy ratings is a more feasible method of eliciting QoL in a sample that includes people with severe dementia, many of whom have communication and language difficulties. The use of a dichotomized delusion and hallucination variable limits the ability of the study to fully capture the varied frequency and severity of these symptoms. However, this was necessary to prevent biasing the data toward more severe symptom experience as the focus of the study was to determine if any experience of psychotic symptom would be associated with reduced QoL.

The cross-sectional nature of the study limits the interpretations that can be drawn, and causal relationships cannot be determined.

Fig. 1. Relationship between delusions and QoL mediated by agitation, anxiety, and depression in PwD living in nursing homes.
Additionally, the mediation analysis does not draw any conclusions of directionality. The analyses show that given the possibility of a serial line of neuropsychiatric symptom causality that results in reduced QoL, psychotic symptoms remain a key independent association. Hence, focus on developing treatments directed toward psychotic symptoms is an important priority for researchers and clinicians. It should also be acknowledged that CDR is a staging classification, not a formal classification system for diagnosing dementia, and not all participants therefore had a formal diagnosis of dementia.

Conclusions and Implications

The present findings highlight the impact of psychotic symptoms on reduced QoL in PwD living in nursing homes independent of confounding factors and implicates the urgent need for safe and effective methods of treatment and management. Additionally, the findings of the mediation analyses provide clearer insight into the role of comorbid neuropsychiatric symptoms and in turn will bolster future development of nonpharmacologic treatments for psychotic symptoms and other concurrent neuropsychiatric symptoms in PwD.

Acknowledgments

The article presents data from independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research (PGfAR) Programme (Grant RPPG-060-10133). A.C. and C.B. thank the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, King’s College London for supporting their time for this work. L.C. acknowledges support from the NIHR Applied Research Collaboration South West Peninsula. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health. We are extremely grateful to Becky Jones for her support with feedback on drafts of the manuscript.

Fig. 2. Relationship between hallucinations and QoL mediated by agitation, anxiety, and depression in PwD living in nursing homes.

References

1. Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the Cardiovascular Health Study. JAMA. 2002;288:1475–1483.
2. Zuidema SU, de Jonge JFM, Verhey FJR, et al. Neuropsychiatric symptoms in nursing home patients: factor structure invariance of the Dutch nursing home version of the Neuropsychiatric Inventory in different stages of dementia. Dement Geriatr Cogn Disord. 2007;24:169–176.
3. Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer’s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162:2022–2030.
4. Selbek G, Engedal K, Bergh S. The prevalence and course of neuropsychiatric symptoms in nursing home patients with dementia: a systematic review. J Am Med Dir Assoc. 2013;14:161–169.
5. Scarmeas N, Brandt J, Albert M, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol. 2005;62:1601–1608.
6. Stern Y, Albert M, Brandt J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer’s disease: prospective analyses from the Predictors Study. Neurology. 1994;44:2300–2307.
7. Lyketsos CG, Sheppard JM, Steinberg M, et al. Neuropsychiatric disturbance in Alzheimer’s disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry. 2001;16:1043–1053.
8. Choi A, Ballard C, Martyr A, et al. The impact of auditory hallucinations on “living well” with dementia: findings from the IDEAL programme. Int J Geriatr Psychiatry. 2021;36:1370–1377.
9. Ballard C. Agitation and psychosis in dementia. Am J Geriatr Psychiatry. 2007;15:913–917.
10. Ballard C, Neill D, O’Brien J, et al. Anxiety, depression and psychosis in vascular dementia: prevalence and associations. J Affect Disord. 2000;59:97–106.
11. Hoe J, Hancock G, Livingston G, et al. Changes in the quality of life of people with dementia living in care homes. Alzheimer Dis Assoc Disord. 2009;23:285–290.
12. Martyr A, Nelis SM, Quinn C, et al. Living well with dementia: a systematic review and correlational meta-analysis of factors associated with quality of life, well-being and life satisfaction in people with dementia. Psychol Med. 2018;48:2130–2139.
13. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci. 2006;7:492–500.
14. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191–210.
15. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934–1943.
16. Clare L, Wu YT, Jones IR, et al. A comprehensive model of factors associated with subjective perceptions of “living well” with dementia: findings from the IDEAL study. Alzheimer Dis Assoc Disord. 2019;33:36–41.
17. Small N. Living well until you die. Ann N Y Acad Sci. 2007;1114:194–203.
18. Ballard C, O'Brien J, James L, et al. Quality of life for people with dementia living in residential and nursing home care: the impact of performance on activities of daily living, behavioral and psychological symptoms, language skills, and psychotropic drugs. *Int Psychogeriatr*. 2001;13:93–106.

19. Khoo SA, Chen TT, Ang YH, et al. The impact of neuropsychiatric symptoms on caregiver distress and quality of life in persons with dementia in an Asian tertiary hospital memory clinic. *Int Psychogeriatr*. 2013;25:1991–1999.

20. Mjørud M, Kirkevold M, Røsvik J, et al. Variables associated to quality of life among nursing home patients with dementia. *Aging Ment Health*. 2014;18:1013–1021.

21. Wetzels RB, Zuidema SU, de Jonghe JFM, et al. Determinants of quality of life in nursing home residents with advanced dementia. *Aging Ment Health*. 2014;18:1021–1027.

22. Cordner Z, Blass DM, Rabins PV, et al. Quality of life in nursing home residents with and without dementia—cross-sectional analyses from the COSMOS study. *Int J Geriatr Psychiatry*. 2019;34:683–691.

23. Samus QM, Rosenblatt A, Steele C, et al. The association of neuropsychiatric symptoms and environment with quality of life in assisted living residents with dementia. *Gerontologist*. 2005;45(suppl 1):19–26.

24. Baaneree S, Smith SC, Lamping DL, et al. Quality of life in dementia: more than just cognition. An analysis of associations with quality of life in dementia. *J Neurol Neurosurg Psychiatry*. 2006;77:146–148.

25. Woods RT, Nelin SM, Martyr A, et al. What contributes to a good quality of life in early dementia? Awareness and the QoL-AD: a cross-sectional study. *Health Qual Life Outcomes*. 2014;12:94.

26. van Kooten J, van der Wouden JC, Sikkes SAM, et al. Pain, neuropsychiatric symptoms, and quality of life of nursing home residents with advanced dementia in the Netherlands: a cross-sectional study. *Alzheimer Dis Assoc Disord*. 2017;31:315–321.

27. Habiger TF, Floe E, Achterberg WP, et al. Psychosis symptoms in nursing home residents with and without dementia—cross sectional analyses from the COSMOS study. *Int J Geriatr Psychiatry*. 2019;34:683–691.

28. Rostad HM, Puts MTE, Cvancarova Småstuen M, et al. Associations between pain and quality of life in severe dementia: a Norwegian cross-sectional study. *Dement Geriatr Cogn Dis Extra*. 2017;7:109–121.

29. van Dam PH, Caljouw MAA, Slettebo DD, et al. Quality of life and pain medication use in persons with advanced dementia living in long-term care facilities. *J Am Med Dir Assoc*. 2019;20:1432–1437.

30. Abbey J, Piller N, Bellis AD, et al. The Abbey Pain Scale: a 1-minute numerical assessment tool for the assessment of the quality of life of patients with dementia: the WHELD research programme including two RCTs. In: *Programme Grants for Applied Research, no. 8.6. NIHR Journals Library*. 2020.

31. Ballard C, Orrell M, Moniz-Cook E, et al. Improving mental health and reducing antipsychotic use in people with dementia in care homes: the WHELD research programme including two RCTs. In: *Programme Grants for Applied Research, no. 8.6. NIHR Journals Library*. 2020.

32. Whitaker R, Fossey J, Ballard C, et al. Improving Well-being and Health for People with Dementia (WHELD): study protocol for a randomised controlled trial. *Trials*. 2014;15:284.

33. Ballard C, Corbett A, Orrell M, et al. Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: a cluster-randomised controlled trial. *PLoS Med*. 2018;15:e1002500.

34. Lange RT, Hopp GA, Kang N. Psychometric properties and factor structure of the Neuropsychiatric Inventory Nursing Home Version in an elderly neuropsychiatric population. *Int J Geriatr Psychiatry*. 2004;19:440–448.

35. Wood S, Cummings J, Hsu MA, et al. The use of the neuropsychiatric inventory in nursing home residents: characterization and measurement. *Am J Geriatr Psychiatry*. 2000;8:75–83.

36. Crawford JR, Henry JD, Crombie C, et al. Normative data for the HADS from a large non-clinical sample. *Br J Clin Psychol*. 2001;40:429–434.

37. Smith SC, Lamping DL, Banerjee S, et al. Development of a new measure of health-related quality of life for people with dementia: DEMQOL. *Psychol Med*. 2007;37:737–746.

38. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. *J Gerontol*. 1989;44:M77–M84.

39. Alexopoulos GS, Abrams RC, Young RC, et al. Cornell scale for depression in the psychiatric population. *Arch Gen Psychiatry*. 1987;44:737–746.

40. Abbey J, Piller N, Bellis AD, et al. The Abbey Pain Scale: a 1-minute numerical indicator for people with end-stage dementia. *Int J Palliat Nurs*. 2004;10:6–13.

41. O’Bryant SE. Staging dementia using Clinical Dementia Rating Scale: a 1-minute numerical indicator for people with end-stage dementia. *Arch Neurol*. 2001;58:2394–2397.

42. Hayes AF. Staging dementia using Clinical Dementia Rating Scale: a 1-minute numerical indicator for people with end-stage dementia. *Arch Neurol*. 2008;65:1091–1095.

43. Hayes AF, Proctor SP. Staging dementia using Clinical Dementia Rating Scale: a 1-minute numerical indicator for people with end-stage dementia. *Arch Neurol*. 2001;58:2394–2397.

44. Gomez-Gallego M, Gomez-Garcia J, Ato-Lozano E. Addressing the bias problem in the assessment of the quality of life of patients with dementia: Determinants of the accuracy and precision of the proxy ratings. *J Nutr Health Aging*. 2015;19:365–372.
**Supplementary Table 1**

Characteristic of People With and Without Psychotic Symptoms

|                     | Delusions, n or Mean (SD) | Hallucinations, n or Mean (SD) |
|---------------------|---------------------------|-------------------------------|
|                     | No            | Yes        | No   | Yes   |
| Sex                 |               |            |      |       |
| Male                | 237           | 46         | 246  | 38    |
| Female              | 563           | 124        | 583  | 104   |
| Ethnicity           |               |            |      |       |
| Asian               | 8             | 1          | 9    | 0     |
| African             | 9             | 2          | 9    | 2     |
| Black Caribbean     | 18            | 7          | 24   | 1     |
| White               | 757           | 158        | 777  | 139   |
| Mixed               | 5             | 1          | 6    | 0     |
| Other               | 3             | 1          | 4    | 0     |
| Marital status      |               |            |      |       |
| Single              | 105           | 15         | 107  | 13    |
| Married             | 167           | 37         | 170  | 35    |
| Divorced            | 48            | 10         | 53   | 5     |
| Separated           | 7             | 0          | 6    | 1     |
| Widowed             | 459           | 104        | 476  | 87    |
| Long-term partnership| 6            | 1          | 6    | 1     |
| Antipsychotic drug prescription |       |            |      |       |
| Yes                 | 149           | 44         | 155  | 39    |
| No                  | 633           | 122        | 658  | 97    |
| Age, y              | 84.54 (9.15)  | 84.73 (8.22)| 84.67 (8.81) | 84.00 (9.93) |